[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100515081":3},{"organization":4,"armGroups":7,"interventions":22,"overallOfficials":28,"centralContacts":29,"locations":35,"responsibleParty":133,"collaborators":28,"id":135,"slug":136,"hasResults":137,"nctId":138,"briefTitle":139,"officialTitle":140,"acronym":28,"eligibilityCriteria":141,"healthyVolunteers":137,"sex":142,"minAge":143,"maxAge":28,"enrollmentInfo":144,"targetDuration":28,"studyType":147,"phases":148,"briefSummary":151,"conditions":152,"keywords":154,"overallStatus":52,"whyStopped":28,"lastUpdateSubmitDate":159,"lastUpdatePostDateStruct":160,"startDateStruct":163,"completionDateStruct":165,"leadSponsor":167,"locationsCount":169},{"fullName":5,"class":6},"Skyline Therapeutics","INDUSTRY",[8,14,18],{"label":9,"type":10,"description":11,"interventionNames":12},"Phase I: Low dose","EXPERIMENTAL","SKG0106 One-Time Intraocular Injection Dose Level 1",[13],"Genetic: SKG0106",{"label":15,"type":10,"description":16,"interventionNames":17},"Phase I: Medium dose","SKG0106 One-Time Intraocular Injection Dose Level 2",[13],{"label":19,"type":10,"description":20,"interventionNames":21},"Phase I: High dose","SKG0106 One-Time Intraocular Injection Dose Level 3",[13],[23],{"type":24,"name":25,"description":26,"armGroupLabels":27,"otherNames":28},"GENETIC","SKG0106","SKG0106 is a recombinant adeno-associated virus (AAV) vector-based in vivo gene therapeutic product",[19,9,15],null,[30],{"name":31,"role":32,"phone":33,"phoneExt":28,"email":34},"Yongqin Wang","CONTACT","+86 18616737445","yongqin.wang@skytx.com",[36,50,61,77,92,103,112,120,128],{"facility":37,"status":38,"city":39,"state":40,"zip":41,"country":42,"countryCode":43,"cosmosGeoPoint":44,"geoPoint":49,"contacts":28},"Retina Vitreous Associates of Florida - Saint Petersburg","NOT_YET_RECRUITING","St. Petersburg","Florida","33711","United States","US",{"type":45,"coordinates":46},"Point",[47,48],-82.67927,27.77086,{"lat":48,"lon":47},{"facility":51,"status":52,"city":53,"state":54,"zip":55,"country":42,"countryCode":43,"cosmosGeoPoint":56,"geoPoint":60,"contacts":28},"Ophthalmic Consultants of Boston","RECRUITING","Boston","Massachusetts","02114",{"type":45,"coordinates":57},[58,59],-71.05977,42.35843,{"lat":59,"lon":58},{"facility":62,"status":52,"city":63,"state":64,"zip":65,"country":42,"countryCode":43,"cosmosGeoPoint":66,"geoPoint":70,"contacts":71},"Retina Consultants of Texas","Katy","Texas","77494",{"type":45,"coordinates":67},[68,69],-95.8244,29.78579,{"lat":69,"lon":68},[72,74],{"name":73,"role":32,"phone":28,"phoneExt":28,"email":28},"Marie Chin",{"name":75,"role":76,"phone":28,"phoneExt":28,"email":28},"Charles C Wykoff, MD","PRINCIPAL_INVESTIGATOR",{"facility":78,"status":52,"city":79,"state":80,"zip":81,"country":42,"countryCode":43,"cosmosGeoPoint":82,"geoPoint":86,"contacts":87},"Wagner Kapoor Research Institute","Norfolk","Virginia","23502",{"type":45,"coordinates":83},[84,85],-76.28522,36.84681,{"lat":85,"lon":84},[88,90],{"name":89,"role":32,"phone":28,"phoneExt":28,"email":28},"Chris Riebling",{"name":91,"role":76,"phone":28,"phoneExt":28,"email":28},"Alan Wagner, MD",{"facility":93,"status":52,"city":94,"state":95,"zip":28,"country":96,"countryCode":97,"cosmosGeoPoint":98,"geoPoint":102,"contacts":28},"The Second Hospital Of Anhui Medical University","Hefei","Anhui","China","CN",{"type":45,"coordinates":99},[100,101],117.28083,31.86389,{"lat":101,"lon":100},{"facility":104,"status":52,"city":105,"state":106,"zip":28,"country":96,"countryCode":97,"cosmosGeoPoint":107,"geoPoint":111,"contacts":28},"Zhejiang Provincial People's Hospital","Hangzhou","Zhejiang",{"type":45,"coordinates":108},[109,110],120.16142,30.29365,{"lat":110,"lon":109},{"facility":113,"status":52,"city":114,"state":106,"zip":28,"country":96,"countryCode":97,"cosmosGeoPoint":115,"geoPoint":119,"contacts":28},"Eye Hospital, WMU (Zhejiang Eye Hospital)","Wenzhou",{"type":45,"coordinates":116},[117,118],120.66682,27.99942,{"lat":118,"lon":117},{"facility":121,"status":52,"city":122,"state":28,"zip":28,"country":96,"countryCode":97,"cosmosGeoPoint":123,"geoPoint":127,"contacts":28},"Beijing Hospital","Beijing",{"type":45,"coordinates":124},[125,126],116.39723,39.9075,{"lat":126,"lon":125},{"facility":129,"status":52,"city":122,"state":28,"zip":28,"country":96,"countryCode":97,"cosmosGeoPoint":130,"geoPoint":132,"contacts":28},"Peking Union Medical College Hospital",{"type":45,"coordinates":131},[125,126],{"lat":126,"lon":125},{"type":134,"investigatorFullName":28,"investigatorTitle":28,"investigatorAffiliation":28,"oldNameTitle":28,"oldOrganization":28},"SPONSOR","100515081","phase-1-phase-iii-study-of-skg0106-intravitreal-injection-in-patients-with-neovascular-age-related-macular-degeneration-namd-100515081",false,"NCT05986864","Phase I\u002FII Study of SKG0106 Intravitreal Injection in Patients With Neovascular Age-related Macular Degeneration (nAMD)","Phase I\u002FII Study to Evaluate the Safety and Preliminary Efficacy of SKG0106 Intravitreal Injection in Patients With Neovascular Age-related Macular Degeneration (nAMD)","Inclusion criteria:\n\n1. Voluntary and able to sign a dated ICF prior to any study-related procedures and able to complete the study as required by the protocol;\n2. Aged ≥ 50 years at screening;\n\n   Study Eye:\n3. Diagnosis of nAMD as determined by the PI;\n4. Active CNV lesions secondary to age-related macular degeneration (AMD);\n5. Subjects must have been responsive to anti-VEGF therapy as assessed by the PI prior to study treatment.\n\nExclusion Criteria:\n\n1. Any active intraocular or periocular infection or active intraocular inflammation (e.g., infectious conjunctivitis, keratitis, scleritis, endophthalmitis, infectious blepharitis, uveitis) in the study eye at baseline;\n2. Retinal pigment epithelial tear in the study eye at screening;\n3. Current vitreous hemorrhage in the study eye or history of vitreous hemorrhage within 4 weeks prior to baseline;\n4. Any condition that, in the opinion of the investigator, may limit visual acuity improvement in the study eye;\n5. History of retinal detachment or active retinal detachment in the study eye;\n6. Any prior gene therapy.","ALL","50 Years",{"count":145,"type":146},68,"ESTIMATED","INTERVENTIONAL",[149,150],"PHASE1","PHASE2","This is a phase 1\u002F2 clinical study to evaluate the safety, preliminary efficacy, immunogenicity, and pharmacokinetic (PK) characteristics of SKG0106 in subjects with nAMD. Based on results from the phase 1 dose escalation study, the phase 2 expansion study will be conducted.",[153],"Neovascular Age-related Macular Degeneration",[155,156,157,158],"AMD","wet AMD","wAMD","nAMD","2025-01-08",{"date":161,"type":162},"2025-01-09","ACTUAL",{"date":164,"type":162},"2024-02-23",{"date":166,"type":146},"2026-01-30",{"name":168,"class":6},"Skyline Therapeutics (US) Inc.",9]